Anand Mehra
CIK 1590102 · last filed 2026-06-08
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
ONCE price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
MENLO PARK, CA 94025
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ACRS | Director | 2,637,976 | $3.63 | $9.59M | -$11.19M | 18 | 2026-06-08 |
| Merus N.V. (MRUS) Delisted | Director | — | $90.00 | — | $0 | 7 | 2025-12-12 |
| Spark Therapeutics, Inc. (ONCE) Delisted | Director | 0 | — | — | -$85.72M | 25 | 2019-12-17 |
| MARINUS PHARMACEUTICALS, INC. (MRNS) Delisted | Director | — | $0.55 | — | $0 | 3 | 2016-08-05 |
| AERIE PHARMACEUTICALS INC (AERI) Delisted | Director | 471,291 | $15.25 | $7.19M | -$42.21M | 5 | 2015-04-16 |
Recent Filings · Page 4 of 6
58 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2017-03-01 | Spark Therapeutics, Inc. (ONCE) Delisted | Sell (S) | −84,654 | -$5.50M | EDGAR |
| 2017-02-22 | Spark Therapeutics, Inc. (ONCE) Delisted | Sell (S) | −7,535 | -$489.9K | EDGAR |
| 2017-02-16 | Spark Therapeutics, Inc. (ONCE) Delisted | Sell (S) | −35,347 | -$2.30M | EDGAR |
| 2017-02-13 | Spark Therapeutics, Inc. (ONCE) Delisted | Sell (S) | −37,411 | -$2.43M | EDGAR |
| 2017-02-07 | Spark Therapeutics, Inc. (ONCE) Delisted | Sell (S) | −25,334 | -$1.65M | EDGAR |
| 2017-01-12 | ACRS | Sell (S) | −750,000 | -$21.19M | EDGAR |
| 2016-12-19 | Spark Therapeutics, Inc. (ONCE) Delisted | Sell (S) | −349,656 | -$18.69M | EDGAR |
| 2016-12-13 | Spark Therapeutics, Inc. (ONCE) Delisted | Sell (S) | −122,532 | -$6.76M | EDGAR |
| 2016-08-12 | Spark Therapeutics, Inc. (ONCE) Delisted | Sell (S) | −29,963 | -$1.80M | EDGAR |
| 2016-08-10 | Spark Therapeutics, Inc. (ONCE) Delisted | Sell (S) | −100 | -$6.0K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.